Source-grounded facts extracted from IONIS PHARMACEUTICALS INC's SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
IONIS PHARMACEUTICALS INC shareholders approved Ratify the Audit Committee's selection of Ernst & Young LLP as independent auditors for the 2026 fiscal year at the 2026-06-04 meeting.
“Proposal 5: Ratify the Audit Committee’s selection of Ernst & Young LLP as independent auditors for the 2026 fiscal year: FOR AGAINST ABSTAIN BROKER NON-VOTES 148,893,646 4,000,539 150,525 0 The Company’s stockholders approved the foregoing proposal.”
IONIS PHARMACEUTICALS INC shareholders approved Approve an amendment of the Amended and Restated 2000 Employee Stock Purchase Plan to increase the number of shares of common stock authorized for issuance under such plan by 750,000 shares and to remove the termination date of the plan at the 2026-06-04 meeting.
“Proposal 4: Approve an amendment of the Amended and Restated 2000 Employee Stock Purchase Plan to increase the number of shares of common stock authorized for issuance under such plan by 750,000 shares and to remove the termination date of the plan: FOR AGAINST ABSTAIN BROKER NON-VOTES 140,348,001 332,204 58,810 12,305,695 The Company’s stockholders approved the foregoing proposal.”
IONIS PHARMACEUTICALS INC shareholders approved Approval of an amendment of the Amended and Restated Ionis Pharmaceuticals, Inc. 2011 Equity Incentive Plan to increase the aggregate number of shares of common stock authorized for issuance under such plan by 9,500,000 shares to an aggregate of 52,000,000 shares at the 2026-06-04 meeting.
“Proposal 3 : Approval of an amendment of the Amended and Restated Ionis Pharmaceuticals, Inc. 2011 Equity Incentive Plan to increase the aggregate number of shares of common stock authorized for issuance under such plan by 9,500,000 shares to an aggregate of 52,000,000 shares: FOR AGAINST ABSTAIN BROKER NON-VOTES 108,377,084 32,303,288 58,643 12,305,695 The Company’s stockholders approved the foregoing proposal.”
IONIS PHARMACEUTICALS INC shareholders approved An advisory vote on the compensation paid to the Company's executive officers at the 2026-06-04 meeting.
“Proposal 2 : An advisory vote on the compensation paid to the Company’s executive officers, including the following resolution: “RESOLVED, that Ionis’ stockholders approve, on an advisory (nonbinding) basis, the compensation of the named executive officers, as disclosed in this Proxy Statement for the 2026 Annual Meeting of Stockholders pursuant to the compensation disclosure rules of the Securities and Exchange Commission.” FOR AGAINST ABSTAIN BROKER NON-VOTES 135,537,973 5,088,105 112,937 12,305,695 The Company’s stockholders approved the foregoing proposal.”
IONIS PHARMACEUTICALS INC shareholders approved Election of directors to hold office until the 2029 Annual Meeting at the 2026-06-04 meeting.
“The Company held its virtual Annual Meeting of Stockholders on June 4, 2026. The stockholders considered five proposals, each of which is described in more detail in the Company’s definitive proxy statement dated April 23, 2026. Proposal 1: Election of directors to hold office until the 2029 Annual Meeting: FOR AGAINST ABSTAIN BROKER NON-VOTES Spencer R. Berthelsen 119,824,353 20,816,547 98,115 12,305,695 Joan E. Herman 135,599,646 5,076,895 62,474 12,305,695 The Company’s stockholders elected the foregoing candidates by affirmative votes by a majority of the votes of the shares represented in person or by proxy at the meeting and entitled to vote in the election of directors.”
Peter N. Reikes was appointed as member of the Board of Directors at IONIS PHARMACEUTICALS INC.
“the Company also appointed Peter N. Reikes as a member of the Company’s Board effective June 4, 2026”
Ludwig N. Hantson was appointed as member of the Board of Directors at IONIS PHARMACEUTICALS INC.
“appointed Ludwig N. Hantson as a member of the Company’s Board effective June 4, 2026”
IONIS PHARMACEUTICALS INC reported first quarter 2026 results: revenue $246 million. Guidance raised.
“First Quarter 2026 Summary Financial Results (1): Three months ended March 31, 2026 2025 (amounts in millions) Total revenue $ 246 $ 132 Operating expenses $ 364 $ 278 Operating expenses on a non-GAAP basis $ 321 $ 249 Loss from operations $ (118 ) $ (146 ) Loss from operations on a non-GAAP basis $ (75 ) $ (117 )”
IONIS PHARMACEUTICALS INC issued convertible note to initial purchasers for $770.0 million aggregate principal amount.
“On November 17, 2025, Ionis Pharmaceuticals, Inc. (the “Company”) completed its previously announced private offering (the “Offering”) of $770.0 million aggregate principal amount of 0.00% Convertible Senior Notes due 2030 (the “Notes”), including the exercise in full of the initial purchasers’ option to purchase up to an additional $70.0 million principal amount of Notes.”
IONIS PHARMACEUTICALS INC incurred convertible notes of $770.0 million aggregate principal amount with U.S. Bank Trust Company, National Association at 0.00% maturing December 1, 2030.
“On November 17, 2025, Ionis Pharmaceuticals, Inc. (the “Company”) completed its previously announced private offering (the “Offering”) of $770.0 million aggregate principal amount of 0.00% Convertible Senior Notes due 2030 (the “Notes”), including the exercise in full of the initial purchasers’ option to purchase up to an additional $70.0 million principal amount of Notes.”
Holly Kordasiewicz was appointed as executive vice president and chief development officer at IONIS PHARMACEUTICALS INC.
“On June 12, 2025, the Company issued a press release announcing that Holly Kordasiewicz, Ph.D., currently senior vice president, neurology, will succeed Dr. Richard Geary Ph.D. in the role of executive vice president and chief development officer beginning in January 2026.”
Richard Geary retired as executive vice president and chief development officer at IONIS PHARMACEUTICALS INC.
“On June 12, 2025, Ionis Pharmaceuticals, Inc. (the “ Company ”) issued a press release announcing that Richard Geary Ph.D., executive vice president and chief development officer, will retire effective January 2026.”
IONIS PHARMACEUTICALS INC updated its first quarter ended March 31, 2024 guidance (reaffirmed).
“On May 7, 2024, Ionis Pharmaceuticals, Inc. (the “ Company ”) issued a press release announcing the Company’s financial results for the quarter ended March 31, 2024.”
Onaiza Cadoret-Manier departed as executive vice president, chief global product strategy and operations officer at IONIS PHARMACEUTICALS INC.
“Onaiza Cadoret-Manier, executive vice president, chief global product strategy and operations officer, is leaving the company to pursue another opportunity.”
Kyle Jenné was appointed as executive vice president, commercial at IONIS PHARMACEUTICALS INC.
“Kyle Jenné has rejoined Ionis as executive vice president, commercial”
IONIS PHARMACEUTICALS INC entered into a license with Otsuka Pharmaceutical Co., Ltd. (effective 2023-12-18).
“On December 18, 2023, Ionis Pharmaceuticals, Inc. issued a press release announcing it has entered into a license agreement with Otsuka Pharmaceutical Co., Ltd. (“ Otsuka ”) under which Otsuka obtains exclusive rights in Europe to commercialize donidalorsen, an investigational prophylactic treatment for hereditary angioedema (HAE).”
Michael Yang was appointed as Director at IONIS PHARMACEUTICALS INC.
“On December 14, 2023, the Board of Directors (“ Board ”) of Ionis Pharmaceuticals, Inc. (the “ Company ”) appointed Michael Yang as a member of the Company’s Board effective immediately.”
IONIS PHARMACEUTICALS INC updated its the third quarter of 2023 guidance (reaffirmed).
“today reported financial results for the third quarter of 2023.”
IONIS PHARMACEUTICALS INC entered into a collaboration with Roche (effective 2023-09-27).
“On September 27, 2023, Ionis Pharmaceuticals, Inc. issued a press release announcing it has entered into an agreement with Roche for two early-stage programs for RNA-targeting investigational medicines for the treatment of Alzheimer’s disease and Huntington’s disease.”
IONIS PHARMACEUTICALS INC reported financial results for second quarter 2023; six months ended June 30, 2023.
“Ionis reports second quarter 2023 financial results”
IONIS PHARMACEUTICALS INC entered into Agreement with Novartis Pharma AG (effective 2023-08-03).
“On August 3, 2023, Ionis Pharmaceuticals, Inc. (the “ Company ”) issued a press release announcing that the Company entered into a collaboration and license agreement (the “ Agreement ”) with Novartis Pharma AG (“ Novartis ”) to discover, develop and commercialize a novel medicine for patients with lipoprotein(a)-driven cardiovascular disease.”
IONIS PHARMACEUTICALS INC incurred convertible notes of $575.0 million aggregate principal amount at 1.75% per year maturing June 15, 2028.
“On June 12, 2023, Ionis Pharmaceuticals, Inc. (the “Company”) completed its previously announced private offering (the “Offering”) of $575.0 million aggregate principal amount of 1.75% Convertible Senior Notes due 2028”
IONIS PHARMACEUTICALS INC entered into Indenture with U.S. Bank Trust Company, National Association valued at $575.0 million aggregate principal amount (effective 2023-06-12).
“On June 12, 2023, Ionis Pharmaceuticals, Inc. (the “Company”) completed its previously announced private offering (the “Offering”) of $575.0 million aggregate principal amount of 1.75% Convertible Senior Notes due 2028 (the “Notes”), including the exercise in full of the initial purchasers’ option to purchase up to an additional $75.0 million principal amount of Notes.”
IONIS PHARMACEUTICALS INC shareholders approved Ratify the Audit Committee’s selection of Ernst & Young LLP as independent auditors for the 2023 fiscal year at the 2023-06-01 meeting.
“Proposal 6: Ratify the Audit Committee’s selection of Ernst & Young LLP as independent auditors for the 2023 fiscal year: FOR AGAINST ABSTAIN BROKER NON-VOTES 127,567,008 2,276,019 92,266 0”
IONIS PHARMACEUTICALS INC shareholders approved Ratification of increasing the vesting of future initial stock option and restricted stock unit awards to new non-employee Directors from one year to three years at the 2023-06-01 meeting.
“Proposal 5 : Ratification of increasing the vesting of future initial stock option and restricted stock unit awards to new non-employee Directors from one year to three years: FOR AGAINST ABSTAIN BROKER NON-VOTES 100,409,115 19,628,971 73,939 9,823,268”
IONIS PHARMACEUTICALS INC shareholders approved Approval of an amendment of the Ionis Pharmaceuticals, Inc. 2011 Equity Incentive Plan to increase the aggregate number of shares of common stock authorized for issuance under such plan by 5,500,000 shares to an aggregate of 35,200,000 shares at the 2023-06-01 meeting.
“Proposal 4 : Approval of an amendment of the Ionis Pharmaceuticals, Inc. 2011 Equity Incentive Plan to increase the aggregate number of shares of common stock authorized for issuance under such plan by 5,500,000 shares to an aggregate of 35,200,000 shares: FOR AGAINST ABSTAIN BROKER NON-VOTES 88,929,162 31,115,758 67,105 9,823,268”
IONIS PHARMACEUTICALS INC shareholders approved Approval, on an advisory basis, of the frequency of future advisory votes on executive compensation at the 2023-06-01 meeting.
“Proposal 3 : Approval, on an advisory basis, of the frequency of future advisory votes on executive compensation: 1 YEAR 2 YEARS 3 YEARS ABSTAIN 119,423,064 134,181 475,080 79,700”
IONIS PHARMACEUTICALS INC shareholders approved Approval, on an advisory basis, of the compensation paid to the Company’s executive officers at the 2023-06-01 meeting.
“Proposal 2 : Approval, on an advisory basis, of the compensation paid to the Company’s executive officers, including the following resolution: “RESOLVED, that Ionis’ stockholders approve, on an advisory basis, the compensation of the named executive officers, as disclosed in this Proxy Statement for the 2023 Annual Meeting of Stockholders pursuant to the compensation disclosure rules of the Securities and Exchange Commission.” FOR AGAINST ABSTAIN BROKER NON-VOTES 117,265,241 2,746,636 100,148 9,823,268”
IONIS PHARMACEUTICALS INC shareholders approved Election of directors to hold office until the 2026 Annual Meeting at the 2023-06-01 meeting.
“Proposal 1: Election of directors to hold office until the 2026 Annual Meeting: FOR WITHHELD BROKER NON-VOTES Spencer R. Berthelsen 91,194,334 28,917,691 9,823,268 Joan E. Herman 115,174,011 4,938,014 9,823,268 B. Lynne Parshall 101,641,511 18,470,514 9,823,268 Joseph H. Wender 88,160,292 31,951,733 9,823,268”
IONIS PHARMACEUTICALS INC reported financial results for the fourth quarter and full year ended December 31, 2022.
“On February 22, 2023, Ionis Pharmaceuticals, Inc. (the “ Company ”) issued a press release announcing the Company’s financial results for the quarter and fiscal year ended December 31, 2022.”
IONIS PHARMACEUTICALS INC entered into Purchase Agreement with Royalty Pharma Investments 2019 ICAV valued at $500,000,000 (effective 2023-01-08).
“On January 8, 2023, Ionis Pharmaceuticals, Inc. (the “ Company ”) and its wholly-owned subsidiary, Akcea Therapeutics, Inc. (the “ Subsidiary ”) entered into a royalty purchase agreement (the “ Purchase Agreement ”) with Royalty Pharma Investments 2019 ICAV, an Irish collective asset-management vehicle (“ Royalty Pharma ”), pursuant to which the Company and the Subsidiary sold to Royalty Pharma: (i) the Company’s right, title and interest in and to: (A) in respect of net sales by Biogen Idec International Holding Ltd (“ Biogen Idec ”) and Biogen MA (“ Biogen MA ”, and together with Biogen Idec, “ Biogen ”) between January 1, 2023 and December 31, 2027, 25%, and (B) in respect of net sales by Biogen Idec commencing on January 1, 2028, 45% of the royalties payable to the Company on annual worldwide net sales up to $1,500,000,000 pursuant to that certain Development, Option and License Agreement by and between the Company and Biogen Idec dated January 3, 2012, as amended (the “ 2012 Bioge”
IONIS PHARMACEUTICALS INC reported full year 2022 results: revenue >$575 million, net income <$350 million. Guidance raised.
“Item 2.02 Results of Operations and Financial Condition. In connection with the Company’s entry into the Agreement, the Company increased its full year 2022 guidance for operating expenses and net loss, on a non-GAAP basis, to incorporate the upfront payment to Metagenomi, all as reflected in the table below. Full Year 2022 Guidance Revised Guidance Previous As of Q3 2022 Revenue >$575 million >$575 million Operating expenses on a non-GAAP basis $900-$925 million $825-$850 million Net loss on a non-GAAP basis <$350 million <$275 million Cash, cash equivalents and short-term investments ~2.0 billion ~$2.0 billion”
IONIS PHARMACEUTICALS INC entered into Collaboration and License Agreement with Metagenomi, Inc. valued at $80 million upfront fee, plus target selection fees, development/regulatory/sales milestones, and ro (effective 2022-11-10).
“On November 10, 2022, Ionis Pharmaceuticals, Inc. (the “ Company ”) entered into a collaboration and license agreement (the “ Agreement ”) with Metagenomi, Inc. (“ Metagenomi ”) to research, develop and commercialize investigational medicines for up to eight potential genetic targets using gene editing technologies.”
Frederick Muto retired as Member of the Board of Directors at IONIS PHARMACEUTICALS INC.
“On July 15, 2022, Frederick Muto, a member of the Board of Directors (“ Board ”) of Ionis Pharmaceuticals, Inc. (the “ Company ”), notified the Company that he is retiring from the Company’s Board effective July 15, 2022.”
Peter N. Reikes resigned as Director at IONIS PHARMACEUTICALS INC.
“On November 19, 2021, Peter N. Reikes, a member of the Board of Directors (“Board”) and Finance Committee of the Board of Ionis Pharmaceuticals, Inc. (the “Company”), notified the Company that he is resigning from the Company’s Board effective November 21, 2021.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.